A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Stage III non-small-cell lung cancer (NSCLC) is seen in a relatively heterogeneous group of
patients with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of
different treatment modalities are not clear. The purpose of this study is to evaluate the
efficacy and safety of neoadjuvant double-drug chemotherapy containing platinum plus
anlotinib hydrochloride in patients with stage III(N2) non-small-cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University